This is a working overview of REV-ERB, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-06 and is reviewed periodically as new material appears.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Derived from published structure. |
| Molecular weight | 437.94 g/mol | Calculated value. |
| Appearance | White to off-white solid | Typical for purified research samples. |
| Solubility | DMSO, ethanol; low in water | Class: poorly water-soluble. |
| Typical storage | -20 °C, desiccated, protected from light | Limits degradation. |
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
=== Approval ratings === In a survey conducted by Ipespe/Febraban and released in February 2023, Lula's third government was rated as good or excellent by 40% of Brazilians, regular by 27%, and bad or terrible by 28%, while 5% did not respond. In the following month, between the 2nd and 6th, Ipec conducted an analysis that was released on the 19th; in it, 41% of Brazilians rated the government as "good or excellent", 30% considered the administration "regular", and 24% thought it was "bad or terrible"; 5% did not know or preferred not to respond. In this way, Lula began his third term with higher approval than his predecessor, Jair Bolsonaro, who in March 2019 was considered "good or excellent" by 34%. Regarding confidence in Lula, 53% of the population said they trusted him, while 43% stated that they did not trust him and 4% preferred not to express an opinion. Finally, the survey found that the president's way of governing had the approval of 57% of Brazilians. On 29 and 30 March, Datafolha interviewed 2,028 people in 126 municipalities, and the Lula government was rated as excellent or good by 38%, regular by 30%, and bad or terrible by 29% of respondents. On 23 May, according to a new survey, 54% of respondents approved of the government, while 39% of respondents disapproved of the government. In June 2023, according to a new Ipec survey, the Lula government had the approval of 37% of the population, while 32% considered it regular, 28% disapproved of it, and 3% did not know how to answer.
=== Research === AM-1006 – undefined mechanism of action (short-acting subperceptual psychoactive drug) – substance use disorders EQL-101 – undefined mechanism of action (non-hallucinogenic non-cardiotoxic ibogaine derivative) – substance use disorders – Equulus Therapeutics Ibogaine – various actions, oneirogen/hallucinogen – substance-related disorders Mebufotenin (5-MeO-DMT; LSR-2000) – non-selective serotonin receptor agonist, serotonin 5-HT1A and 5-HT2A receptor agonist, serotonergic psychedelic – alcoholism MYCO-004 (patch-delivered tryptamine compound) – undefined mechanism of action, serotonergic psychedelic – smoking withdrawal, substance-related disorders Research programme: Ibogaine derivatives - MindMed/Nextage Therapeutics – various actions – opioid-related disorders Research programme: monoclonal antibody therapeutics - CounterX Therapeutics – undefined mechanism of action – opioid-related disorders Research programme: psychedelic and empathogenic compounds subcutaneous - Bexson Biomedical – undefined mechanism of action – substance-related disorders Substance-related disorders therapeutics - Tessara Therapeutics/Xylo Bio/University of Sydney – neuronal plasticity modulators – substance-related disorders VVZ-2471 – metabotropic glutamate mGlu5 receptor antagonist, serotonin 5-HT2A receptor antagonist – opioid-related disorders
Groth examined the change in symmetry of a crystal as a result of the replacement of a hydrogen atom by another univalent atom or radical. Morphotropy is also referred to as isogonism in which each vertex is surrounded by the same kinds of face in the same or reverse order, and with the same angles between corresponding faces. In 1897 Wilhelm Ostwald introduced Ostwald's rule, to describe the formation of polymorphs. The rule states that usually the less stable polymorph crystallizes first. Ostwald's rule is not a universal law but a common tendency observed in nature.
Sources: en.wikipedia.org
The 2010 study demonstrated Salvia divinorum's closest relative to be Salvia venulosa—a rare and endemic Salvia that is native to Colombia, growing in shaded, wooded gullies at 1,500 to 2,000 m (4,900 to 6,600 ft) elevation. It also showed that Salvia divinorum does not belong to the Salvia section Dusenostachys, as believed earlier. The genetic study also indicated that Salvia venulosa was likely misplaced into Salvia section Tubiflorae, and that it may not be related to other Colombian Salvia species, though further tests are needed. A 2013 follow-up analysis of more Salvia species reported the same result. The origin of Salvia divinorum was still a mystery as of 1993, one of only three plants in the extensive genus Salvia (approximately 900 species) with unknown origins—the other two being Salvia tingitana and Salvia buchananii.
==== Laser-assisted bioprinting ==== In a 2012 study, Koch et al. focused on whether Laser-assisted BioPrinting (LaBP) can be used to build multicellular 3D patterns in natural matrix, and whether the generated constructs are functioning and forming tissue. LaBP arranges small volumes of living cell suspensions in set high-resolution patterns. The investigation was successful, the researchers foresee that "generated tissue constructs might be used for in vivo testing by implanting them into animal models" (14). As of this study, only human skin tissue has been synthesized, though researchers project that "by integrating further cell types (e.g. melanocytes, Schwann cells, hair follicle cells) into the printed cell construct, the behavior of these cells in a 3D in vitro microenvironment similar to their natural one can be analyzed", which is useful for drug discovery and toxicology studies.
Making models out of clay before beginning to build, the city planners remained consistent with Inca architecture and laid out a city that separated the agriculture and urban areas. Before construction began the engineers had to assess the spring and whether it could provide for all of the city’s anticipated citizens. After evaluating the water supply, the civil engineers designed a 2,457-foot (749 m)-long canal to what would become the city’s center. The canal descends the mountain slope, enters the city walls, passes through the agricultural sector, then crosses the inner wall into the urban sector, where it feeds a series of fountains. The fountains are publicly accessible and partially enclosed by walls that are typically about 1.2 m high, except for the lowest fountain, which is a private fountain for the Temple of the Condor and has higher walls. At the head of each fountain, a cut stone conduit carries the water to a rectangular spout, which is shaped to create a jet of water suitable for filling aryballos–a typical Inca clay water jug. The water collects in a stone basin in the floor of the fountain, then enters a circular drain that delivers it to the approach channel for the next fountain. The Incas built the canals on steady grades, using cut stones as the water channels. Most citizens worked on the construction and maintenance of the canal and irrigation systems, bronze and stone tools to complete the water-tight stone canals.
Sources: en.wikipedia.org
== How it works == The spark ion source consists of a vacuum chamber containing the electrodes, which is called the spark housing. The tips of the electrodes are composed of or containing the sample and are electrically connected to the power supply. Extraction electrodes create an electric field that accelerate the generated ions through the exit slit.
The taxonomic workforce remains insufficient for documenting lichen diversity. Lendemer (2021) found that only 14% of lichen-related research papers published in 2018–2020 included taxonomic work, while Lücking (2020) estimated that the current community of lichen taxonomists is only a fraction of what would be needed for a complete inventory. Expertise is particularly lacking in biodiversity-rich tropical regions where most undescribed species likely occur. However, infrastructure improvements are helping address these gaps. Since 2012–2013, mandatory registration of new fungal names in repositories like MycoBank has been widely adopted, with over 97% of new lichen species from 2018 to 2020 properly registered. Additionally, citizen scientists using platforms such as iNaturalist increasingly contribute to species discovery when collaborating with professional taxonomists. Nomenclatural challenges arise as lichen systematics increasingly encounters cryptic species. Environmental DNA studies reveal numerous uncharacterized fungal lineages, including potential lichenicolous fungi, but ICN rules require physical type specimens for species description. This creates difficulties for documenting diversity found only in environmental samples. The community generally discourages naming taxa known only from sequences to avoid proliferating dubious names. A related concern is taxonomic inflation—the risk that genomic data could lead to naming every population variant.
Following TNF-R1 and Fas activation in mammalian cells a balance between proapoptotic (BAX, BID, BAK, or BAD) and anti-apoptotic (Bcl-Xl and Bcl-2) members of the Bcl-2 family are established. This balance is the proportion of proapoptotic homodimers that form in the outer-membrane of the mitochondrion. The proapoptotic homodimers are required to make the mitochondrial membrane permeable for the release of caspase activators such as cytochrome c and SMAC. Control of proapoptotic proteins under normal cell conditions of nonapoptotic cells is incompletely understood, but in general, Bax or Bak are activated by the activation of BH3-only proteins, part of the Bcl-2 family.
Sources: en.wikipedia.org
SR9009 is a synthetic REV-ERB agonist used in laboratory research. It is not an approved drug, and its effects in humans are not well characterized. It is often sold as a research chemical under the name Stenabolic.
No. SR9009 targets the nuclear receptors REV-ERBα and REV-ERBβ, not the androgen receptor. This mechanism differs from selective androgen receptor modulators and from exercise mimetics that act on PPARδ.
Published evidence is mainly preclinical, using cell cultures and animal models. Controlled human trials are not well documented in the public literature. Claims about human performance or health effects therefore remain unsupported by robust clinical data.
Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.